CGRP receptor antagonist olcegepant (BIBN4096BS) does not prevent glyceryl trinitrate-induced migraine.

What Was Tested

This randomized controlled trial looks at Dipeptides in the context of migraine.

There is a striking similarity between the migraine-provoking effect of the nitric oxide (NO) donor glyceryl trinitrate (GTN) and that of calcitonin gene-related peptide (CGRP).

The researchers tested the hypothesis that NO releases CGRP to cause the delayed migraine attack after GTN.

Who Took Part

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and crossover study.

Because people in this Dipeptides study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Dipeptides study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Dipeptides could be set against what happens without it.

Each person switched between Dipeptides and the comparison at some point, usually with a gap in between.

What Was Measured

The researchers tested the hypothesis that NO releases CGRP to cause the delayed migraine attack after GTN.

The subject headings attached to it are Calcitonin Gene-Related Peptide Receptor Antagonists, Dipeptides, Migraine Disorders, Nitroglycerin, Piperazines, Quinazolines and Vasodilator Agents.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Dipeptides in people with migraine.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2010 (Cephalalgia : an international journal of headache), a journal based in England.

More context: Migraine research.